The early prevention of asthma in atopic children (EPAAC) study. A multi-country, double blind, placebo (PLC) controlled, randomized, parallel group trial: evaluation of the efficacy and safety of levocetirizine (LCTZ) (5 mg/mL oral drops -0.125 mg/kg b.w. b.i.d. [twice daily]) administered for 18 months in preventing the onset of asthma in 12 to 24 months old children who suffer from atopic dermatitis and are sensitized to grass pollen and / or house dust mite allergens.
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Levocetirizine (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Acronyms EPAAC
- Sponsors UCB
- 01 Sep 2007 Tolerability results have been published.
- 22 Jul 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History